One of the things we hear most consistently from pharmacovigilance (PV) leaders is some version of the same frustration: significant investment has gone into safety systems, case processing workflows, and reporting infrastructure, and yet bottlenecks persist that seem impossible to resolve. 

When we dig into where those bottlenecks actually live, the answer is almost always the same. 

They start at intake. Not inside the safety system. Before it. 

Adverse event information reaches PV teams from markets around the world, arriving in different languages, different document formats, and through different channels: email attachments from local affiliates, PDFs from call centers, literature reports, and scanned or handwritten forms from markets where digital submission isn’t yet standard. A substantial share comes directly from patients and consumers, not clinicians. These reports are written in everyday language and often arrive as free-text narratives or photographs of packaging, labels, and prescriptions. 

Before any of that information can move through a centralized safety workflow, it has to become usable. That means identifying the source, routing it correctly, translating it into English, reviewing it for accuracy, formatting it appropriately, and delivering it to the right place at the right time. 

Each step looks manageable in isolation. Together, they create a surprisingly persistent operational gap between receiving safety information and being able to act on it. 

“The bottleneck isn’t always where it appears to be. In global pharmacovigilance, some of the most persistent friction starts before a case ever reaches the safety system.”

Intake Is More Than an Entry Point 

The word ‘intake’ undersells what is actually happening. 

In global pharmacovigilance, intake is not simply the moment a document arrives. It is the beginning of a chain of decisions and handoffs that shape everything that follows. 

When a safety document arrives in a language the centralized team cannot process directly, translation becomes an early dependency. The translated content has to accurately preserve product names, adverse events, dates, dosage information, and medical context. A nuance lost at this stage does not just create a quality issue. It creates a correction that has to be caught and resolved further downstream, usually at greater cost and effort. 

But accuracy is only part of it. 

Depending on the document type, the translated version also has to reproduce the layout of the original, not just the words. When a laboratory report’s tables collapse, it can become unclear which result belongs to which parameter. When a structured form loses its layout, critical information can become difficult to interpret. These are not edge cases. They are common enough that desktop publishing support is a regular part of multilingual safety document preparation. 

What looks like a translation task is often a multi-step operational process, and the distinction matters when organizations are trying to understand where their workflows are actually losing time. 

Where the Workflow Starts to Fracture 

The problem is not usually any single step. It is what happens between them. 

A document arrives. Someone identifies the language and figures out the requirements. The file gets routed for translation. A translator, human, machine, or both, produces the English content. Quality review takes place. Corrections are made. Formatting may need to be reconstructed. The finished document gets delivered to the right team or system. 

In a well-connected environment, that sequence runs smoothly. In a fragmented one, built around email threads, manual handoffs, and disconnected tools, every transition is an opportunity for delay, inconsistency, or rework. 

Pharmacovigilance does not run on forgiving timelines. Expedited Individual Case Safety Reports carry 7 and 15-day regulatory clocks depending on seriousness and market. Periodic reports have fixed submission windows. With clocks this short, translation has to be part of the workflow rather than a stop along it. Every extra step, queue and gap between systems adds time, and time absorbed at intake comes straight out of assessment, reporting and submission. 

As global case volumes grow and language requirements expand, processes built around individual handoffs and disconnected tools become harder to scale. The question stops being how to translate a document faster, and starts being something more fundamental: how to move multilingual safety information from intake into the PV workflow with fewer manual steps, without sacrificing the quality and control the process demands. 

Automation Can Help. But Automation Alone Is Not the Answer. 

This is where AI is creating a genuinely interesting opportunity, and where the conversation in the industry sometimes gets ahead of itself. 

Translation technology can significantly accelerate the initial conversion of multilingual safety content into English. Automation can reduce repetitive administrative steps. These are real efficiency gains, and they matter in an environment where volume is growing and timelines are not getting longer. 

But pharmacovigilance is not an environment where speed can come at the expense of accuracy. 

Safety content is full of details where precision matters: product names that look similar across languages, adverse event descriptions that can hinge on a single qualifier, and dosage information where even a decimal point can change meaning. 

AI can move this content through the translation process much faster, reducing repetitive manual work and the number of human touchpoints along the way. Fewer handoffs also mean fewer opportunities for information to be mistyped, misrouted, or delayed. 

Human expertise remains an important part of that workflow, focused where it adds the most value: reviewing the translated content, resolving ambiguity, and confirming that the final document is ready to move into the safety process. 

For PV teams, that combination can make multilingual intake faster and more efficient while maintaining the level of accuracy the work demands. 

What Better Multilingual Intake Could Look Like 

In practice, a more connected multilingual intake process might look something like this: 

• A source document enters the workflow 
• The source is prepared for processing: scanned, image-based, and handwritten content is converted into editable content that AI-enabled technology can process 
• The source language is identified and the content is translated into English using AI-enabled technology 
• A dedicated, specialized linguistic team reviews the translation 
• The document’s original structure and formatting are preserved or recreated where needed 
• The completed English document is delivered into the client’s established safety workflow, ready to be processed, not prepared 

The distinction worth holding onto is this: the goal is not to give PV teams another tool to manage. It is to reduce the number of manual steps they have to manage at all, so that by the time safety information reaches the people responsible for processing it, the hard work of making it usable has already been done. 

The Bigger Opportunity Starts Earlier Than You Think 

Most of the conversation about AI in pharmacovigilance right now focuses on what happens once safety information is already inside the system: extraction, case processing, coding, signal detection, narrative generation. Those are important opportunities and they are getting well-deserved attention. 

But there is also significant value in looking upstream. 

Before any of that sophisticated analysis can happen, global safety information first has to become accessible, accurate, and usable by the teams responsible for processing it. For organizations operating across multiple markets and languages, that upstream step is where a lot of friction quietly accumulates, and where better processes can create meaningful operational value. 

The next opportunity for PV automation may not begin deeper inside the safety system. It may begin earlier, at the moment safety information first enters the workflow. 

That is a conversation worth having, and one we are increasingly having with PV teams who are thinking seriously about where their next efficiency gains are going to come from.